Pharmacologic strategies for augmenting cognitive performance in schizophrenia

Biological Psychiatry

Volumn 45, Issue 1, 1999, Pages 1-16

  Friedman, Joseph I ^a   Temporini, Humberto ^a   Davis, Kenneth L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Cognitive; Dopamine; Norepinephrine; Remediation; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; CYCLOSERINE; DONEPEZIL; DOPAMINE 1 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; ECOPIPAM; GLUTAMATE RECEPTOR; GUANFACINE; HALOPERIDOL; LEVODOPA; MILACEMIDE; MUSCARINIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NORADRENALIN; OXIDOPAMINE; PHYSOSTIGMINE; RACLOPRIDE; RISPERIDONE; RITANSERIN; SULPIRIDE; TACRINE; UNINDEXED DRUG; XANOMELINE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; LEARNING DISORDER; LIVER TOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; PERFORMANCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCHIZOPHRENIA; WORKING MEMORY;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CATECHOLAMINES; COGNITION; DOPAMINE; HUMANS; NOREPINEPHRINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032968147     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00287-X     Document Type: Review

References (193)

1. Addington J., Addington D., Matycka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res. 4:1991;123-134.
2. Adolfsson R., Gottfries C.G., Roos B.E., Winblad B. Changes in brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry. 135:1979;216-223.
3. Aggleton J., Keith A., Rawlins J., Hunt P., Sahgal A. Removal of the hippocampus and transection of the fornix produce comparable deficits on delyed non-match to position by rats. Behav Brain Res. 52:1992;61-71.
4. Aigner T., Mishkin M. The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol. 45:1986;81-87.
5. Anlezark G.M., Crow T.J., Greenway A.P. Impaired learning and decreased cortical norepinephrine after bilateral locus coeruleus lesions. Science. 181:1973;682-684.
6. Anrade R., Aghajanian G.K. Opiate and alpha-2 adrenoreceptor-induced hyperpolarization of locus coeruleus neurons in brain slices: Reversal by cyclic adenosine 3′, 5′-monophosphate analogues. J Neurosci. 5:1985;2359-2364.
7. Arendt T., Schugens M., Bigl V. The cholinergic system and memory: Amelioration of ethanol-induced memory dysfunction by physostigmine in rat. Acta Neurobiol Exp. 50:1990;251-261.
8. Arnsten A.F.T., Goldman-Rakic P.G.R. Selective prefrontal cortical projections to the region of the locus ceruleus and raphe nuclei in the rhesus monkey. Brain Res. 306:1984;9-18.
9. Arnsten A.F.T., Goldman-Rakic P.S. Alpha-2 adrenergic mechanisms in prefromtal cortex associated with cognitive decline in aged nonhuman primates. Science. 230:1985;1273-1276.
10. Arnsten A.F.T., Cai J.X., Goldman-Rakic P.S. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci. 8:1988;4287-4297.
11. Arnsten A.F.T., Cai J.X., Murphy B.L., Goldman-Rakic P.S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl). 116:1994;143-151.
12. Arnsten A.F.T., Steere J.C., Hunt R.D. The contribution of alpha-2 noradrenergic mechanisms to prefrontal cortical cognitive function. Arch Gen Psychiatry. 53:1996;448-455.
13. Baddeley A. Working memory. Science. 255:1992;556-559.
14. Bannon M.J., Roth R. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev. 35:1983;53-67.
15. Bartus R., Johnson H. Short term memory in the rhesus monkey: Disruption from the anticholinergic scopolamine. Pharmacol Biochem Behav. 5:1976;39-46.
16. Bartus R., Uehara Y. Physostigmine and recent memory: Effects in young and aged nonhuman primates. Science. 206:1979;1085-1087.
17. Beracochea D., Micheau J., Jaffard R. Memory deficits following chronic ethanol consumption in mice: Relationships with hippocampal and cortical cholinergic activities. Pharmacol Biochem Behav. 42:1992;749-753.
18. Berman K.F., Weinberger D.R. Functional localization in the brain in schizophrenia. Tasman A., Goldfinger S.M. American Psychiatric Press Review of Psychiatry. vol 10:1991;24-59 American Psychiatric Press, Washington, DC.
19. Berman K.F., Illowsky B.P., Weinberger D.R. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: IV. Further evidence for regional and behavioral specificity. Arch Gen Psychiatry. 45:1988;616-622.
20. Bilder R., Lipshitz-Broch L., Reiter G., Geisler S., Mayerhoff D., Lieberman J. Intellectual deficit in first episode schizophrenia, evidence for progressive deterioration. Schizophr Bull. 18:1992;437-448.
21. Bird E.D., Spokes E.G., Iversen L.L. Brain norepinephrine and dopamine in schizophrenia. Science. 204:1974;93-94.
22. Blozovski D., Cudennec A., Garrigou D. Deficits in passive avoidance learning following atropine in the developing rat. Psychopharmacology (Berl). 54:1977;139-144.
23. Bondareff W, Mountjoy CQ, Roth M (1981): Selective loss of neurons or origin of adrenergic projection to cerebral cortex in senile dementia. Lancet 783-784.
24. Boyajian C.L., Leslie F.M. Pharmacological evidence for alpha-2 receptor heterogeneity: Differential binding properties of [3H] rauwolscine and [3H] idazoxan in rat brain. J Pharmacol Exp Ther. 241:1987;1092-1098.
25. Breier A., Schreiber J., Dyer J., Pickar D. NIMH longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arch Gen Psychiatry. 48:1991;239-246.
26. Bridge T.P., Kleinman J.E., Karoum F., Wyatt R.J. Postmortem central catecholamines and ante mortem cognitive impairment in elderly schizophrenics and controls. Biol Psychiatry. 14:1985;57-61.
27. Brito G., Davis B., Stopp L., Stanton M. Memory and the septohippocampal cholinergic system in the rat. Psychopharmacology (Berl). 81:1983;315-320.
28. Brozoski T., Brown R., Rosvold H., Goldman P. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys. Science. 205:1979;929-932.
29. Bubser M., Schmidt W.J. 6-OHDA lesions of the rat prefrontal cortex increase locomotor activity and impair acquisition of delayed alternation tasks but do not affect uninterrupted tasks in the radial maze. Behav Brain Res. 37:1990;157-168.
30. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 36:1994;717-725.
31. Cai J.X., Arnsten A.F. Dose dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther. 283:1997;183-189.
32. Callahan M., Kinsora J., Harbaugh R., Reeder T., Davis R. Continuous icv infusion of scopolamine impairs sustained attention of rhesus monkeys. Neurobiol Aging. 14:1993;147-151.
33. Carli M., Robbins T.W., Evenden J.L., Everitt B.J. Effects of lesions to ascending noradrenergic neurons on performance of a 5-choice serial reaction task in rats. Implications for theories of dorsal noradrenergic bundle functions based on selective attention and arousal. Behav Brain Res. 9:1983;361-380.
34. Carter C., Robertson L., Nordahl T., Chaderjian M., Kraft L., O'Shora-Celaya L. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients. Biol Psychiatry. 40:1996;930-932.
35. Cascella N.G., Macciareli P., Cavallini C., Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open label study. J Neural Transm Gen Sect. 95:1994;105-111.
36. Christie J., Shering A., Ferguson J., Glen A. Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer's presenile dementia. Br J Psychiatry. 138:1981;46-50.
37. Cleghorn J., Kaplan R., Szechtman B., Szechtman M., Brown G. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res. 3:1990;211-219.
38. Cole B.J., Robbins T.W. Forebrain norepinephrine: Role in controlled information processing in the rat. Neuropsychopharmacology. 7:1992;129-141.
39. Cortes R., Gueye B., Pazos A., Probs A., Palacios J.M. Dopamine receptors in the human brain: Autoradiographic distribution of D1 sites. Neuroscience. 28:1989;263-273.
40. Coull J.T. Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. Drugs Aging. 5:1994;116-126.
41. Cross A.J., Crow T.J., Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Reduced dopamine beta hydroxylase activity on Alzheimer's disease. Br Med J. 282:1981;93-94.
42. Crow T.J. Cortical synapses and reinforcement. Nature. 219:1968;736-737.
43. Crow T.J., Baker H.F., Cross A.J., et al. Monoamine mechanisms in chronic schizophrenia: Post-mortem neurochemical findings. Br J Psychiatry. 134:1979;249-256.
44. Cummings J., Benson D. The role of the nucleus basalis of Meynert in dementia: Review and reconsideration. Alzheimer Dis Assoc Disord. 1:1987;128-145.
45. Damask S., Bovenkerk K., de la Pena G., Hoversten K., Valentine A., Meador-Woodruff J. Differential effect of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. Mol Brain Res. 41:1996;241-249.
46. Daniel D.G., Weinberger D.R., Jones D.W., et al. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J Neuropsychiatry. 1:1989;377-384.
47. Daniel D.G., Weinberger D.R., Jones D.W., et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 11:1991;1907-1917.
48. Danjou P., Warot D., Hergueta T., Lacomblez Bouhours P., Puech A.J. Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in health subjects: Some trait anxiety-independent responses. Int Clin Psychopharmacol. 7:1992;73-79.
49. Davidson M., Harvey P., Bergman R., et al. Effects of the D1 agonist SKF-39393 combined with haloperidol in schizophrenic patients. Arch Gen Psychiatry. 47:1990;190-191. [letter].
50. Davidson M., Harvey P., Powchik P., et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 152:1995;197-207.
51. Davidson M., Harvey P.D., Welsh K.A., Powchik P., Putnam K.M., Mohs R.C. Cognitive functioning in late life schizophrenia: A comparison of elderly schizophrenic patients with Alzheimer's disease. Am J Psychiatry. 153:1996;1274-1279.
52. Davis K.L., Mohs R., Tinklenberg J., Pfefferbaum A., Hollister L., Kopell B. Physostigmine: Improvement of long-term memory in normal humans. Science. 201:1978;272-274.
53. Davis K.L., Hollander E., Davidson M., Davis B., Mohs R., Horvath T. Induction of depression with oxotremorine in Alzheimer's disease patients. Am J Psychiatry. 144:1987;468-471.
54. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry. 148:1991;1474-1486.
55. Dawson G., Heyes C., Iversen S. Pharmacological mechanisms and animal models of cognition. Behav Pharmacol. 3:1992;285-297.
56. Devauges V., Sara S.J. Activation of the noradrenergic system facilitates an attention shift in the rat. Behav Brain Res. 39:1990;19-29.
57. Didriksen M. Effects of antipsychotics on cognitive behavior in rats using the delayed non-match to position paradigm. Eur J Pharmacol. 281:1995;241-250.
58. Drachman D. Memory and cognitive function in man. Does the cholinergic system have a specific role? Neurology. 27:1977;783-790.
59. Drachman D., Glosser G., Fleming P., Longenecker G. Memory decline in the aged: Treatment with lecithin and physostigmine. Neurology. 32:1982;944-950.
60. Dunnett S. Comparative effects of cholinergic drugs and lesions of the nucleus basalis or fimbria-fornix on delayed-matching in rats. Psychopharmacology (Berl). 87:1985;357-363.
61. Earle-Boyer E., Serper M., Davidson M., Harvey P. Continuous Performance Test in schizophrenic patients: Stimulus and medication effects on performance. Psychiatry Res. 37:1991;47-56.
62. Eichenbaum H., Otto T., Cohen N. Two functional components of the hippocampal memory system. Behav Brain Sci. 17:1994;449-518.
63. Elliott R., McKenna P.J., Robbins T.W., Sahakian B.J. Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med. 25:1995;619-630.
64. El-Mallack R., Kirch D., Shelton R., et al. The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. J Neuropsychiatry Clin Neurosci. 3:1991;383-386.
65. Elsworth J., Leahy D., Roth R., Redmond D. Homovanillic acid concentration in brain, CSF and plasma as indicators of central dopamine function in primates. J Neural Transm Gen Sect. 68:1987;51-62.
66. Ezrin-Waters C., Resch L. The nucleus basalis of Meynert. Can J Neurol Sci. 13:1986;8-14.
67. Fadda F., Melis F., Stancampiano R. Increased hippocampal acetylcholine release during a working memory task. Eur J Pharmacol. 307:1996;R1-R2.
68. Farley I.J., Price K.S., McCullouough E., Deck J.H.N., Hordynsky W., Hornykiewicz O. Norepinephrine in chronic paranoid schizophrenia: Above-normal levels in limbic forebrain. Science. 200:1978;456-457.
69. Fields R.B., van Kammen D.P., Peters J.L., et al. Clonidine improves memory function in schizophrenia independently from changes in psychosis: Preliminary findings. Schizophr Res. 1:1988;417-423.
70. Fleming K., Goldberg T., Binks S., Randolph C., Gold J., Weinberger D. Visuospatial working memory in patients with schizophrenia. Biol Psychiatry. 41:1997;43-43.
71. Fleming K., Goldberg T., Gold J., Weinberger D. Verbal working memory dysfunction in schizophrenia: Use of a Brown-Peterson paradigm. Psychiatry Res. 56:1997;155-161.
72. Flynn D., Ferrari-DiLeo G., Mash D., Levey A. Rapid communication: Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem. 64:1995;1888-1891.
73. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. J Psychiatr Res. 12:1975;189-198.
74. Gold J., Carpenter C., Randolph C., Goldberg T., Weinberger D. Auditory working memory and WCST performance in schizophrenia. Arch Gen Psychiatry. 54:1997;159-165.
75. Goldberg T., Weinberger D.R. Effects of the neuroleptic medications on the cognition of patients with schizophrenia: A review of recent studies. J Clin Psychiatry. 57:(suppl 9):1996;62-65.
76. Goldberg T.E., Weinberger D.R., Berman K.F., Pliskin N.H., Podd M.H. Further evidence for a dementia of cortical type in schizophrenia? A controlled study of teaching the WCST. Arch Gen Psychiatry. 44:1987;1008-1014.
77. Goldberg T., Weinberger D., Pliskin N., Berman K., Podd M. Recall memory deficit in schizophrenia: A possible manifestation of prefrontal dysfunction. Schizophr Res. 2:1989;251-257.
78. Goldberg T., Bigelow L., Weinberger D., Daniel D., Kleinman J. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry. 148:1991;78-84.
79. Goldberg T., Greenberg R., Griffin S., et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 162:1993;43-48.
80. GoldmanRakic PS (1987): Circuitry of the primate prefrontal cortex and the regulation of behavior by representational memory. In: Plum F, editor. Handbook of Physiology: The Nervous System, Higher Function of the Brain. Bethesda, MD: American Physiological Society.
81. Goldman-Rakic P. Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory. Carroll B.J., Barrett J.E. Psychopathology and the Brain. 1991;1-23 Raven Press, New York.
82. Goldman-Rakic P. Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA. 93:1996;13473-13480.
83. Goldman-Rakic P.S., Lidow M.S., Gallager D.W. Overlap of dopaminergic, adrenergic and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex. J Neurosci. 10:1990;2125-2138.
84. Goldman-Rakic P.S., Lidow M.S., Smiley J.F., Williams M.S. The anatomy of dopamine in monkey and human prefrontal cortex. J Neural Transm Suppl. 36:1992;163-177.
85. Golf D.C., Tsai G., Manoach D.S., Coyle J.T. Dose finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
86. Golf D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 153:1996;1628-1630.
87. Green M. What are the consequences of the neurocognitive deficits in schizophrenia? Am J Psychiatry. 153:1996;321-330.
88. Green M., Marshall B., Wirshing W., et al. Does risperidone improve verbal working memory in treatment resistant schizophrenia? Am J Psychiatry. 154:1997;799-804.
89. Hagan J., Salamone J., Simpson J., Iversen S., Morris R. Place navigation in the rat is impaired by lesions of the medial septum and diagonal band, but not nucleus basalis magnocellularis. Behav Brain Res. 27:1988;9-20.
90. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H. Improvement in cognitive function and psychiatric symptoms in schizophrenic patients receiving clozapine. Biol Psychiatry. 34:1993;702-712.
91. Hamburg M.D., Cohen R.P. Memory access pathway: Role of adrenergic versus cholinergic neurons. Pharmacol Biochem Behav. 1:1973;295-300.
92. Hampson R.E., Rogers G., Lynch G., Deadwyler S.A. Facilitative effects of the AMPAkine CX516 on short-term memory in rats: Enhancement of delayed-nonmatch-to-sample-performance. J Neurosci. 18:1998;2740-2747.
93. Hampson R.E., Rogers G., Lynch G., Deadwyler S.A. Facilitative effects of the Ampakine CX516 on short-term memory in rats: Correlations with hippocampal neuronal activity. J Neurosci. 18:1998;2748-2763.
94. Haroutunian V., Davidson M., Kanof P., et al. Cortical cholinergic markers in schizophrenia. Schizophr Res. 12:1994;137-144.
95. Haroutunian V, Powchik P, Purohit DP, et al (in press): Cognitive deficits without a cholinergic cause: Choline acetyltransferase activity in the parietal cortex of 95 elderly schizophrenics. Neuroscience.
96. Harvey J.A. Serotonergic regulation of associative learning. Behav Brain Res. 73:1996;47-50.
97. Harvey P., Keefe R. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums. 2:1997;41-55.
98. Harvey P., Lombardi J., Leibman M., et al. Cognitive impairment and negative symptoms in schizophrenia, a prospective study of their relationship. Schizophr Res. 22:1996;223-231.
99. Hoff A., Faustman W., Wieneke M., et al. The effect of clozapine on symptom reduction, neurocognitive function and clinical management in treatment refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 15:1996;361-369.
100. Hollander E., Davidson M., Mohs R., et al. RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects. Biol Psychiatry. 22:1987;1067-1078.
101. Ingvar D.H., Franzen G. Abnormalities in cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand. 50:1974;425-462.
102. Ingvar M., Ingerson J., Davis M., et al. Enhancement by an AMPAkine of memory encoding in humans. Exp Neurol. 146:1997;553-559.
103. Jentsch J., Tran A., Le D., Youngren K., Roth R. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99.
104. Jentsch J., Redmond D., Elsworth J., Taylor J., Youngren K., Roth R. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long term administration of phencyclidine. Science. 277:1997;953-955.
105. Kahn R., Harvey P., Davidson M., et al. Neuropsychological correlates of central monoamine function chronic schizophrenia: Relationship between CSF metabolites and cognitive function. Schizophr Res. 11:1994;217-224.
106. Kalaria R.N., Andorn A.C., Tabaton M., Whitehouse P.J., Harik S.I., Unnerstall J.R. Adrenergic receptors in aging and Alzheimer's disease: Increased beta-2 receptors in prefrontal cortex and hippocampus. J Neurochem. 53:1989;1772-1781.
107. Kemali D., Del-Vecchio M., Maj M. Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol Psychiatry. 17:1982;711-717.
108. Kobilka B.K., Matsui H., Kobilka T.S., et al. Cloning and sequencing, and expression of the gene coding for the human platelet alpha-2 adrenergic receptor. Science. 238:1987;650-656.
109. Kugler J., Krauskoff R., Seus R., Brecht H.M., Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. J Clin Pharmacol. 10:1980;715-805.
110. Lake C.R., Sternberg D.E., van Kammen D.P., et al. Schizophrenia: Elevated cerebrospinal fluid norepinephrine. Science. 207:1980;331-333.
111. Leslie F.M., Loughlin S.E., Sternberg D.B., McGaugh J.L., Young I., Zornetzer S.F. Noradrenergic changes and memory loss in aged mice. Brain Res. 359:1985;292-299.
112. Levey A., Kitt C., Simonds W., Price D., Brann M. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype specific antibodies. J Neurosci. 11:1991;3218-3226.
113. Levin E.D., Wilkerson A., Jones J.P., Christopher N.C., Briggs S.J. Prenatal nicotine effects on memory in rats: Pharmacological and behavioral challenges. Brain Res Dev Brain Res. 97:1996;207-215.
114. Lewis D.A. The catecholaminergic innervation of primate prefrontal cortex. J Neural Transm Suppl. 36:1992;179-200.
115. Lidow M., Goldman-Rakic P. A common action of clozapine, haloperidol and remoxipride on D1 and D2 dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA. 91:1994;4353-4356.
116. Lidow M., Elsworth J., Goldman-Rakic P. Down regulation of the D1 and D5 dopamine receptors in the primate PFC by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther. 281:1997;597-603.
117. Lynch G., Granger R., Ambros-Ingerson J., Davis C.M., Kessler M., Schehr R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol. 145:1997;89-92.
118. Mair R.G., McEntee W.J. Cognitive enhancement in Korsakoff's psychosis by clonidine: A comparison with L-Dopa and ephedrine. Psychopharmacology (Berl). 88:1986;374-380.
119. Mandel R., Chen A., Connor D., Thal L. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: Effects on performance in the water maze task and cortical cholinergic markers. J Pharmacol Exp Ther. 251:1989;612-619.
120. Mann D.M.A., Yates P.O. Dementia and cerebral noradrenergic innervation. Br Med J. 282:1981;474-485.
121. Mann D.M.A., Lincoln L., Yates P.O., Stamp J.E., Toper S. Changes in monamine containing neurons in the human CNS in senile dementia. Br J Psychiatry. 136:1980;533-541.
122. Mason S.T., Iversen S.D. Theories of dorsal bundle extinction effects. Brain Res Rev. 1:1979;107-137.
123. McAlonan G., Wilkinson L., Robbins T., Everitt B. The effects of AMPA-induced lesions of the septohippocampal cholinergic projection on aversive conditioning to explicit and contextual cues and spatial learning in the water maze. Eur J Neurosci. 7:1995;281-292.
124. McEntee W.J., Mair R.G. Memory impairment in Korsakoff's Psychosis: A correlation with brain noradrenergic activity. Science. 202:1978;905-907.
125. McGurk S., Green M., Wirshing W., et al. The effects of risperidone vs haloperidol in treatment-resistant schizophrenia: The trail making test. CNS Spectrums. 2:1997;60-64.
126. Meek W., Chuch R., Wenk G., Olton D. Nucleus basalis magnocellularis and medial septal area lesions differentially impair temporal memory. J Neurosci. 7:1987;3505-3511.
127. Miyamoto M., Kato J., Narumi S., Nagaoka A. Characteristics in memory impairment following lesioning of the basal forebrain and septal nucleus in rats. Brain Res. 419:1987;19-31.
128. Moffoot A., O'Carroll R.E., Murray C., Dougall N., Ebmeier K., Goodwin G.M. Clonidine infusion increases uptake of 99mTc-exametazime in anterior cingulate cortex in Korsakoff's psychosis. Psychol Med. 24:1994;53-61.
129. Mohs R., Davis K., Tinklenberg J., Hollister L., Yesavage J., Koppell B. Choline chloride treatment of memory disrder in the elderly. Ann Neurol. 136:1979;1275-1277.
130. Mohs R., Davis K., Tinklenberg J., Hollister L. Choline chloride effects on memory in the elderly. Neurobiol Aging. 1:1980;21-25.
131. Muir J., Dunnett S., Robbins T., Everitt B. Attentional functions of the forebrain cholinergic systems: Effects of intraventricular hemicholinium, physostigmine, basal cortical lesions and intracortical grafts on a multiple choice serial reaction time task. Exp Brain Res. 89:1992;611-622.
132. Murphy B.L., Arnsten A.F.T., Goldman-Rakic P.S., Roth R.H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA. 93:1996;1325-1329.
133. Murphy B., Roth R., Arnsten A. Clozapine reverses the spatial working memory deficits induced by FG7142 in monkeys. Neuropsychopharmacology. 16:1997;433-437.
134. Nestor P., Faux S., McCarley R., Sands S., Horvath T., Peterson A. Neuroleptics improve sustained attention in schizophrenia: A study using signal detection theory. Neuropsychopharmacology. 13:1991;65-71.
135. Nielsen J., Mena A., Williams I., Nocerini M., Liston D. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol. 173:1989;53-64.
136. Nilsson O., Shapino M., Gage F., Olton D., Bjorklund A. Spatial learning and memory following fimbria-fornix transection and grafting of fetal septal neurons to the hippocampus. Exp Brain Res. 67:1987;195-215.
137. Nuechterlein K.H., Dawson M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull. 10:1984;160-200.
138. Oke A.F., Adams R.N. Selective attention dysfunction in adult rats neonatally treated with 6-hydroxydopamine. Pharmacol Biochem Behav. 9:1978;429-432.
139. Okubo Y., Suhara T., Suzuki K., et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
140. Page K., Everitt B., Robbins T., Marston H., Wilkinson L. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: Diffrential dependence on cholinergic neuronal loss. Neuroscience. 43:1991;457-472.
141. Park S. Association of an oculomotor delayed response task and the WCST in schizophrenic patients. Int J Psychophysiol. 27:1997;147-151.
142. Park S., Holtzman P. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry. 49:1992;975-982.
143. Penetar D., McDonough J. Effects of cholinergic drugs on delayed match-to-sample performance of rhesus monkeys. Pharmacol Biochem Behav. 19:1983;963-967.
144. Peskind E.R., Wingerson D., Murray S., et al. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry. 52:1995;774-782.
145. Pickar D., Owen R., Litman R., Konicki P., Gutierrez R., Rappaport M. Clinical and biological response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Arch Gen Psychiatry. 49:1992;345-353.
146. Pilc A., Enna S.J. Activation of alpha-2 adrenergic receptors augments neurotransmitter stimulated cyclic AMP accumulation in rat brain cerebral cortical slices. J Pharmacol Exp Ther. 237:1986;725-730.
147. Putnam K., Harvey P., Parrella M., et al. Symptom stability in geriatric chronic schizophrenic inpatients: A one year follow-up study. Biol Psychiatry. 39:1996;92-99.
148. Raskind MA, Peskind ER, Halter JB, Jimerson DC (1984): Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch Gen Psychiatry 4:343-34.
149. Robbins T., Everitt B., Marston H., Wilkinson J., Jones G., Page K. Comparative effects of ibotenic acid and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: Further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res. 35:1989;221-240.
150. Roberts R.B., Flexner J.B., Flexner L.B. Some evidence for the involvement of adrenergic sites in the memory trace. Proc Natl Acad Sci. 66:1970;310-313.
151. Rogers S., Doody R., Mohs R. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alheimer's disease: Results of a 30 week phase III trial. Neurology. 46:(suppl):1996;A217. [abstract].
152. Rosse R.B., Schwartz B.L., Davis R.E., Deutsch S.I. An NMDA intervention strategy in schizophrenia with "low dose" milacemide. Clin Neuropharmacol. 14:1991;268-272.
153. Rosse R.B., Fay-McCarthy M., Kendrick K., Davis R.E., Deutsch S.I. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 19:1996;444-450.
154. Routsalainen S., Sirvio J., Jakala P., Puumala T., MacDonald E., Riekkinen P. Sr. Differential effects of three 5HT receptor antagonists on the performance of rats in attentional and working memory tasks. Eur Neuropsychopharmacol. 7:1997;99-108.
155. Rupniak N., Spencer T., Field M. Enhanced performance of spatial and visual memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology (Berl). 131:1997;406-410.
156. Sara S.J., Herve-Minvielle A. Inhibitory influence of frontal cortex on locus coeruleus. Proc Natl Acad Sci USA. 92:1995;6032-6036.
157. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science. 251:1991;947-950.
158. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol. 71:1994;515-528.
159. Sawaguchi T., Matsumura M., Kubota K. Dopamine enhances the neuronal activity of spatial short term memory task in the primate prefrontal cortex. Neurosci Res. 5:1988;465-473.
160. Saykin A., Gur R., Gur R., et al. Neuropsychological function in schizophrenia: Selective impairment in learning and memory. Arch Gen Psychiatry. 48:1991;618-624.
161. Saykin A., Shtasel D., Gur R., et al. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry. 51:1994;124-131.
162. Seidman L., Pepple J., Faraone S., et al. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry. 33:1993;575-584.
163. Simon H., Scatton B., LeMoal M. Dopaminergic A10 neurones are involved in cognitive functions. Nature. 286:1980;150-151.
164. Sitaram N., Weingarten H., Gillin J. Human serial learning: Enhancement with arecholine and choline and impairment with scopolamine. Science. 201:1978;274-276.
165. Smith G. Animal models of Alzheimer's disease: Experimental cholinergic denervation. Brain Res Rev. 13:1988;103-118.
166. Steele T., Hodges D., Levesque T., Locke K., Sandage B. The D1 agonist dihydrexidine releases acetylcholine and improves cognition in rats. Ann NY Acad Sci. 777:1996;427-430.
167. Stein L., Wise C.D. Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 5-hydroxydopamine. Science. 171:1971;1032-1036.
168. Stein L., Belluzzi J.D., Wise C.D. Memory enhancement by central administration of norepinephrine. Brain Res. 84:1975;329-335.
169. Strauss M.E., Reynolds K.S., Jayaram G., Tune L. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res. 3:1990;127-129.
170. Summers W., Majovski L., Marsh G., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long term treatment of senile dementia Alzheimer type. N Engl J Med. 315:1986;1241-1245.
171. Tam S.-Y., Roth R. Selective increases in dopamine metabolism in the prefrontal cortex by the anxiogenic β-carboline FG7142. Biochem Pharmacol. 34:1985;1595-1598.
172. Tamlyn D., McKenna P.J., Mortimer A., Lund C., Hammond S., Beddeley A. Memory impairment in schizophrenia: Its extent, affiliations and neuropsychological character. Psychol Med. 12:1992;564-571.
173. Terry R., Masliah E., Salmon D., et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 30:1991;572-580.
174. Thierry A.M., Tassin J.P., Glanc G., Glowinski J. Selective activation of the mesocortical DA system by stress. Nature. 263:1976;242-244.
175. Thomas T.N., Nutt D.J., Holman R.B. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. Br J Pharmacol. 106:1992;430-434.
176. van Kammen D.P., Peters J., van Kammen W.B., et al. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry. 26:1989;176-188.
177. van Kammen D.P., Peters J.L., van Kammen W.B., et al. Clonidine treatment of schizophrenia: Can we predict treatment response? Psychiatry Res. 27:1989;297-311.
178. van Kammen D.P., Peters J., Yao J., et al. Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry. 47:1990;161-168.
179. Van Tol H., Bunzow J., Guan H., et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
180. Verdoux H., Magnin E., Bourgeois M. Neuroleptic effect on neuropsychological test performance in schizophrenia. Schizophr Res. 14:1995;133-139.
181. Vitiello B., Martin A., Hill J., et al. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology. 16:1997;15-24.
182. Wanibuchi F., Nishida T., Yamashita H., et al. Characterization of a novel muscarinic receptor agonist, YM796: Comparison with cholinesterase inhibitors in in-vivo pharmacological studies. Eur J Pharmacol. 265:1994;151-158.
183. Watanabe M., Kodama T., Hikosaka K. Increase in extracellular dopamine in the primate prefrontal cortex during a working memory task. J Neurophysiol. 78:1997;2795-2798.
184. Weinberger D.R., Berman K.F., Zec R.F. Physiological dysfunction of dorsolateral PFC in schizophrenia: I. Regional cerebral blood flow evidence. Arch Gen Psychiatry. 43:1986;114-124.
185. Weinberger D.R., Berman K.F., Illowsky B.P. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: II. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry. 45:1988;609-615.
186. Welsh S.E., Romano A.G., Harvey J.A. Effect of serotonin 5HT(2A/2C) antagonists on associative learning in the rat. Psychopharmacology (Berl). 137:1998;157-163.
187. Wester P., Bengstrom U., Eriksson A., Gezelius C., Hardy J., Winblod B. Ventricular CSF monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J Neurochem. 54:1990;1148-1156.
188. Widerlov E. A critical appraisal of CSF monoamine metabolite studies in schizophrenia. Ann NY Acad Sci. 537:1988;309-323.
189. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 376:1995;572-575.
190. Winkler J., Suhr S., Gage F., Thal L., Fisher L. Essential role of neocortical acetylcholine in spatial memory. Nature. 375:1995;484-487.
191. Woolf N, Butcher L (1989): Cholinergic systems: Synopsis of anatomy and overview of physiology and pathology. In: The Biological Substrates of Alzheimer's Disease. New York: Academic Press, pp 73-86.
192. Yasuda R., Ciesla W., Flores L., et al. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: Distribution of m4 and m5 receptors in the rat brain. Mol Pharmacol. 43:1993;149-157.
193. Youngren K., Moghaddam B., Bunney B., Roth R. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett. 165:1994;41-44.